Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
about
Genome-wide contribution of genotype by environment interaction to variation of diabetes-related traitsWDTC1, the ortholog of Drosophila adipose gene, associates with human obesity, modulated by MUFA intakeImpact of apolipoprotein A5 variants on statin treatment efficacyClinical significance of apolipoprotein A5Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network studyLipid changes due to fenofibrate treatment are not associated with changes in DNA methylation patterns in the GOLDN studyClustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapyConditional random fields for fast, large-scale genome-wide association studiesFine-mapping of lipid regions in global populations discovers ethnic-specific signals and refines previously identified lipid loci.Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma adiponectin concentrations in the GOLDN StudyDisparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites.The effect of a novel intergenic polymorphism (rs11774572) on HDL-cholesterol concentrations depends on TaqIB polymorphism in the cholesterol ester transfer protein gene.Rare LPL gene variants attenuate triglyceride reduction and HDL cholesterol increase in response to fenofibric acid therapy in individuals with mixed dyslipidemiaIL-2 and IL-10 gene polymorphisms are associated with respiratory tract infection and may modulate the effect of vitamin E on lower respiratory tract infections in elderly nursing home residentsHigh throughput prediction of chylomicron triglycerides in human plasma by nuclear magnetic resonance and chemometricsProfiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting.A powerful test of parent-of-origin effects for quantitative traits using haplotypesGenome-wide interaction of genotype by erythrocyte n-3 fatty acids contributes to phenotypic variance of diabetes-related traitsGenetic risk scores associated with baseline lipoprotein subfraction concentrations do not associate with their responses to fenofibrate.ABCD2 alters peroxisome proliferator-activated receptor α signaling in vitro, but does not impair responses to fenofibrate therapy in a mouse model of diet-induced obesityEnrichment of statistical power for genome-wide association studies.Genetic determinants of plasma triglyceridesShort-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.Comparison of genome-wide association methods in analyses of admixed populations with complex familial relationshipsDietary Carbohydrate Modifies the Inverse Association Between Saturated Fat Intake and Cholesterol on Very Low-Density Lipoproteins.High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study.Haplotype analysis of the Apolipoprotein A5 gene in Moroccan patients with the metabolic syndromeA clustering analysis of lipoprotein diameters in the metabolic syndromeGenome-wide association study of triglyceride response to a high-fat meal among participants of the NHLBI Genetics of Lipid Lowering Drugs and Diet Network (GOLDN)Novel insight into mechanisms of cholestatic liver injury.Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemiaProfile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrateDeterminants of plasma apolipoprotein A-V and APOA5 gene transcripts in humans.PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trialEffect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.Genetic analysis of 16 NMR-lipoprotein fractions in humans, the GOLDN study.Profiling serum bile acid glucuronides in humans: gender divergences, genetic determinants, and response to fenofibrate.The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.Rare APOA5 promoter variants associated with paradoxical HDL cholesterol decrease in response to fenofibric acid therapy.
P2860
Q21132476-E2A24B1C-E607-4DCF-9554-8A739CBB43C5Q24314386-8EF99001-E8FC-413C-B935-BCA1B558260BQ28248690-1D1B4E38-B139-44A0-B8C0-05F98C2F6BBDQ28286349-D8BD01DF-4F7B-42DE-9384-16A526486689Q28302934-90BEA07F-C290-4DB5-8FD9-CDC46258487CQ28607159-AEC17614-8A2A-4909-A877-2470E1F8436EQ28728567-78E3E04E-8F64-4E75-B728-9ECD0F995116Q28742726-7061E773-6FC0-4C49-802B-3640D0C08F3EQ30252583-A7F0195D-E3A3-488E-9833-5D8F7B8A00BCQ33441945-BAC8D3A4-F978-4C41-B7FD-EFF5300D72A0Q33493604-991E9324-270D-4C8C-ABE1-F804CD514BF0Q33635575-96ACCF30-1CB3-4268-A4FF-CE8345748CB5Q33833360-4C458C8C-EBDA-42B6-B6B5-C37DC5C8CCABQ33908663-E9CEE886-983E-4AF7-8943-9CD9BCDBE844Q33914973-71BF8576-0C0B-4D6B-BB8B-2FC30CAA527AQ33961753-4FA95E29-3C87-447A-81BE-3A0C2FF2AC73Q34103472-C482B55F-1DF0-4B2C-BA34-306CE689CAEEQ34208519-78FA75F2-C309-4A58-9A45-8DE9748C99F7Q34317998-78D39F74-259A-47DC-9957-2DC1378E82ACQ34360091-963E7085-2F30-4602-A27F-970535554600Q34410312-413EAE54-2FF1-46F8-B921-4CAA1010F4B7Q34503333-C6B4ABB4-6870-41DF-A800-81634D0C1C14Q35111638-03497E4C-6FD0-435D-ABE8-4A1DB1EA43C4Q35129033-ED00D14D-AEC5-465B-B513-95F00E4739C6Q35206915-3F8B9971-8590-4F90-AE6B-62672BFE0D0DQ35509384-1C8A512E-5609-4455-ABEA-8838ADF453A6Q35532345-8D04EF99-6682-4AA6-8710-7475E1285F15Q35677394-82B68F93-F7EE-4354-B949-9F63938BD910Q36068779-7007CB4E-E8E4-4288-BE3C-1D735B279E9EQ36285749-D790D43D-A594-4FB5-B3F2-FE16DD9C0800Q36302771-106FA2C3-5BE0-4C77-AD49-73753B46D087Q36338007-7B4F098E-12BB-4718-8088-292D5F89473BQ36496770-6BC0E00F-8063-4FA3-9C50-773E32E2C9E1Q36528512-67BA229F-79F2-4997-83DF-CBA107F2C00DQ36560348-1F29C3E9-C8CF-4263-B4CD-C120D8EEB2AFQ36687632-07DA99CB-E826-4228-BAE5-DD806EC3AFCCQ36697063-B4E5795C-B81E-47F6-B92F-AB334D5CEA13Q36834217-6E43F78E-6C12-4D0C-80A2-3D8E69C657F2Q36897732-12D09111-1CAD-4182-B4CD-6D78D1EBD462Q36920620-0DE4647F-F06D-47BD-BE18-B5B14CCA0835
P2860
Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@en
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@nl
type
label
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@en
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@nl
prefLabel
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@en
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@nl
P2093
P50
P1476
Fenofibrate effect on triglyce ...... A5 variants: the GOLDN study.
@en
P2093
Chao-Qiang Lai
Dolores Corella
James M Peacock
Laurence D Parnell
Robert J Straka
Xian Adiconis
P304
P356
10.1161/ATVBAHA.107.140103
P407
P577
2007-04-12T00:00:00Z